Pradeep Palazhi
Founder, President & CEOJohn Rekesh
Chief Technology OfficerKevin Fleming
Chief Financial OfficerMichael Evans
Chief Legal OfficerAmitabha Chaudhuri, PhD
Chief Scientific OfficerSudhish Chandran
CTO, FeathersoftManoj Krishnan, PhD
EVP - BioPharma OutreachShirley Straka
EVP, Head of BD – HealthcareSuniti Ponkshe
Chief Growth OfficerDr. M Vijayalakshmi
Chief Clinical OfficerDilip Daswani
EVP - PartnershipsApurva Kalia, PhD
EVP - Platforms and SolutionsThomas C Mathew
Chief Platform OfficerDr. Bobby Cherayil
Clinical Advisor – Head of Immunology and Inflammation ProgramsPradeep Palazhi
Founder, President & CEODan Peterson
Co-founder & ChairmanSam Santhosh
Co-founder & Board MemberKevin Fleming
Chief Financial OfficerMichael Evans
Chief Legal OfficerSudhish Chandran
CTO, FeathersoftDr. Ajikumar (Aji) Parayil
Founder & CEO, ManusDr. Sachdev Sidhu
AdvisorDr. Jame Abraham
Head, Clinical Advisory BoardDr. Vinod Pullarkat
Member, Clinical Advisory BoardDr. Subramonian MS, FRCS
Member, Clinical Advisory BoardDr. Akash J Nair
Head - Clinical Products Liaison, IndiaDr. Raju Rhee
Head of Partnerships - India, UK, Asia & MEAashind Menon
Head of Corporate Development and Global M&AVidhi Malik, PhD
Principal Computational BiologistDr. Vrinda Venu
Senior Computational BiologistDr Shahina K
Computational BiologistDr. Sana Munquad
Computational BiologistChinju John
Scientist, R&D Healthcare and BioinformaticsAnupa Sunny, PhD
R&D Scientist - Bioinformatics & HealthcareManoj Krishnan
Senior VP - Strategy & InnovationDr. Arun Abraham Easow
Head - Marketing & CommunicationsDr. Mohan Sankar
Biomedical ScientistBaiju Sankaran
Head, Global DeliveryUnnikrishnan A
Senior Manager - Healthcare DeliveryPratheek Menon
SVP, ProductsKamalika Roy Choudhury, PhD
Scientific Manager – Data Translation TeamMonisha Ashwin
Product Manager - Therablueprint (Oncology)Dr. Dhanyasree
RadiologistDr. Anagha R. Nair
Medical AdviserDr Gopinath
Medical adviserDr P Parvathy
Lead Computational PathologistSamish Karunalayam
Senior VP- FinanceDr. Unnikrishnan Unniyampurath
Principal ScientistAnil Pillai
Senior VP, Operations, USAparna Kochattil
Sr. Program Manager, USAnand Aravind
Director of Business Development, USKelan Bomar
Director of Sales, USADr Bala Raju
Head of Business Development, UKPradeep Palazhi is an experienced entrepreneur with 30-plus years in various sectors, including healthcare, genomics, precision medicine, synthetic biology, SaaS, and fintech. He has founded or played key roles in several successful companies, such as Loyale Healthcare, ePAY Healthcare, Saath.Care, HealthVidvan, CASHNet, American HealthNet, and Calsoft. Pradeep specializes in building large platforms and SaaS products, as well as managing extensive solutions organizations. He is particularly passionate about developing practical solutions to address significant healthcare challenges that impact patient care and quality of life. His vast business experience and connections span across the US, UK, and India.
Currently, Pradeep serves as the Co-Founder and CEO of ThinkBio.Ai®, Inc., where he focuses on digital biology and precision medicine platforms and solutions. Under his leadership, ThinkBio.Ai® utilizes AI to drive innovations in the biotech, pharmaceutical, and healthcare sectors..
John Rekesh is a seasoned technology expert with over 30 years of industry experience, specializing in Distributed Computing and Artificial Intelligence. With a strong focus on Healthcare and Life Sciences, John has made significant contributions across multiple verticals. He's a thought leader in AI, frequently hosting panel events on Generative AI and authoring insightful pieces on the nature of and surprises within AI models. John has worked with major US, European, and Japanese customers, where he has shaped technology visions and roadmaps for companies worldwide.
John holds multiple patents and has been instrumental in creating over 100 products incorporating diverse technologies. His expertise spans enterprise applications, cybersecurity, and infrastructure, with a strong emphasis on R&D and product engineering. Currently, John's interests lie in AI foundation models in healthcare and life sciences, Responsible AI, and quantum computing. As an AWS Certified Solution Architect and Cloud Practitioner, John combines forward-thinking approaches with practical know-how, enabling organizations to navigate the complex landscape of AI and enterprise solutions.
Kevin is a seasoned executive leader with extensive experience across Healthcare, Technology, FinTech, and Financial Services industries. His impressive career includes roles as CEO, President, CFO, and Managing Director/Partner, as well as Board of Directors positions. Kevin has a strong track record of building substantial enterprise value through various strategies, including growth capital funding, M&A, organic growth, cash flow enhancements, business model transformation, and turnarounds. His notable achievements include successfully leading Loyale Healthcare as CEO & CFO, where he built thriving SaaS Enterprise Technology and FinTech Payments businesses, securing major healthcare networks as customers and ultimately achieving a successful exit. As CEO & CFO of Paradigm Outcomes, he improved clinical outcomes and customer savings to industry-leading standards, doubling revenue and EBITDA, which led to a $300+ million private equity acquisition.
Throughout his career, Kevin has demonstrated expertise in value acceleration and realization, governance roles, capital readiness and funding, and sell-side M&A. As a Senior Partner at Ernst & Young, he provided consulting and audit services to many of the firm’s largest clients, managing complex projects including large-scale M&A. His industry experience spans Healthcare, Financial Services, Technology, Professional Services, and Life Sciences/Pharma. Kevin’s comprehensive skill set includes strategic advisory consulting, business strategy development, risk management, and executive mentoring. His proven ability to drive growth, optimize operations, and create monetizable value positions him at the forefront of today’s dynamic business landscape.
Michael Evans is a seasoned business leader with over three decades of experience in finance and consulting. He spent 34 years as a Senior Partner at Ernst & Young (EY), where he served as Global Industry Leader for the Real Estate, Hospitality and Construction practice. At EY, Michael held senior management roles in the US and Latin America, helping clients improve financial reporting systems, enhance performance, and streamline operations across various service lines.
Currently, Michael is the Managing Director, Chief Financial Officer, and board member for Newport LLC, a partnership focused on middle market companies’ growth and performance. He also serves on several company boards, including one specializing in Artificial Intelligence. A CPA and attorney, Michael shares his expertise as a lecturer on business planning and succession, and as an author for Forbes.com on private company growth. His diverse background and ongoing engagement with emerging technologies provides him with a unique perspective on business strategy and growth.
Amit Chaudhuri, PhD, possesses over two decades of experience in drug discovery and technology advancement, specializing in high throughput proteomics and genomics technologies for the development of better therapies. He is passionate about building integrative data analysis platforms that combine deep domain knowledge with computational biology and AI tools. Over a decade of experience in early drug discovery at mid-size biotech company CuraGen Corporation and at Genentech/Roche provided him with the scientific leadership skills to guide translational research teams at MedGenome, Alstonia Bio, and currently at ThinkBio.Ai®.
As VP and Head of Research at MedGenome, Dr. Chaudhuri led the Immuno-oncology team in developing an integrated platform to discover and develop cancer vaccines, resulting in a US patent in 2019. At Alstonia Bio, he established a high throughput antibody production, purification, and characterization platform to support hit-to-lead generation of engineered multi-specific antibody therapeutics. Now, as CSO of ThinkBio.Ai®, he is building AI-driven integrative platforms to support preclinical-to-clinical translational research for biotech, pharma, and healthcare sectors.
As the CTO and founder of Feathersoft Info Solutions Private Limited, Sudhish Chandran is the driving force behind the company’s technology vision and strategy. He spearheads future technology development, focusing on the incubation of emerging technologies, fostering an innovation ecosystem, and creating industry alliances. With over a decade’s experience in delivering software solutions and cloud architecture to niche industries such as Agritech, Fintech, and Biotech, Sudhish is a seasoned executive. His expertise spans Big Data, Hadoop, AI / ML, Application Management, Enterprise Monitoring, IT Infrastructure, and Cloud Computing. Sudhish excels in implementing risk-free, server-less cloud migrations using agile methodologies.
Sudhish is experienced in building high-performance, large-scale real-time systems, microservices, and web applications. He has a stellar track record of assembling highly skilled development teams and delivering innovative solutions tailored to business needs. He is adept at crafting product and technology strategies, leveraging a strong background in consumer internet/mobile and Cloud/SaaS/Enterprise technologies, and establishing world-class technology teams from the ground up. Sudhish leads all aspects of the product lifecycle, from development and quality assurance to presales and customer support, and excels in managing geographically distributed teams.
Dr.Manoj Krishnan currently serves as the co-founder and Chief Technology Officer of Alstonia Bio in Kochi, where he focuses on developing engineered therapeutics for various human diseases. With a Ph.D. in biophysics from Mahatma Gandhi University, Kerala, Dr. Krishnan completed his postdoctoral training at Yale University School of Medicine, specializing in the systems biology of human immune response. His career then led him to Duke-NUS Medical School in Singapore, where he conducted research on human immune system regulation and the discovery of immunotherapeutic targets using functional genomics approaches as a faculty member.
Dr. Krishnan’s entrepreneurial spirit drove him to co-found a biotechnology company dedicated to cardiovascular drug development. He later joined the mammalian Biofoundry at Ginkgo Bioworks in Boston, where he worked on developing novel gene/cell therapy modalities and biomanufacturing platforms using synthetic biology. Most recently, he headed the pharma platforms and business development at Manus Bio, deploying multiple technologies to develop gene therapy tools and biomanufacturing platforms for various drug modalities using synthetic and systems biology approaches.
Throughout his career, Dr. Krishnan has demonstrated expertise in biophysics, immunology, functional genomics, and synthetic biology, consistently applying his knowledge to advance therapeutic development and biomanufacturing technologies.
Shirley Straka is a highly experienced sales and service professional with over 30 years of expertise in healthcare information technology. Throughout her career, she has demonstrated a strong commitment to customer satisfaction and business growth. She has held key roles in direct sales, sales & account management, project & product management, customer service & education and consulting, while providing IT solutions to large, complex multi-specialty physician group practice organizations, hospitals, and integrated healthcare delivery networks.
Shirley last served as the Executive Vice President of Sales at Loyale, and was responsible for driving enterprise sales, achieving over $12 million in revenue by delivering cutting-edge patient financial engagement technology to large health systems. Before joining Loyale, she was the Chief Sales Officer at Rycan – CPSI, where she led sales efforts for revenue cycle service offerings in a cloud-based environment, achieving an impressive 245% of the sales quota in the first quarter of 2016.
At ZirMed, Shirley excelled as the Regional VP, Business Development, where she was responsible for generating significant revenue through strategic partnerships and expanding the company’s market presence across 18 states in the Midwest. She has a proven track record of rapidly growing pipelines and increasing market awareness through her extensive network of executive relationships.
Shirley’s earlier experience includes senior sales roles at Athenahealth, McKesson, and RelayHealth, where she consistently exceeded sales quotas, managed large accounts, and developed successful sales strategies. Shirley’s extensive experience, strategic insight, and proven ability to drive sales growth make her an asset to any organization looking to expand its reach in the healthcare technology sector.
Suniti Ponkshe is a Managing Director and a Partner at Newport LLC, a boutique business advisory firm that helps CEOs and business owners with their growth, de-risk and value acceleration strategy.
Suniti has been in healthcare and technology space over 35 years working as a consultant as well as an executive. Her successes have been in professional services, technology companies, healthcare, and start-ups. She excels in strategic planning and execution, program/project implementations, business transformation, product development, and operations. She is an advisor, a Board member and an operating executive with a long successful career in the private and public sector working with diverse organizations: healthcare payers, providers, federal agencies, product companies, ranging from startups to large enterprises. She has helped many organizations on increasing their company value, developing strategic plans and exit successfully. Prior to joining Newport, she held executive positions at several organizations including Elevance, Optum, Accenture, IBM and others.
She holds a B.Sc. In Statistics and Economics, and Bachelor of General Laws from Bombay University and M.S. in Management Information Systems from Texas tech University. She has served and continues to serve on several company advisory boards as well as non-profit boards. She co-authored a book on Medical Informatics and has been a guest lecturer to several graduate programs. She enjoys working with C-level executives to address complex problems and helping teams achieve successful outcomes.
Dr. Malayattil Vijayalakshmi is a highly qualified medical specialist with extensive credentials, including an M.D. in Pediatrics, an M.D. in Pediatrics and Adolescent Medicine, and a Fellowship from the American Academy of Pediatrics (FAAP). She also holds a Diploma in Allergy and Asthma and an M.Sc. in Clinical Oncology.
With over 25 years of clinical experience, Dr. Vijayalakshmi is licensed to practice medicine in both California and India. Her diverse career spans hospital and outpatient settings in the United States and India, including managing her own chain of pediatric clinics. Dr. Vijayalakshmi has also made significant contributions to medical research, serving as Ethics Committee and Institutional Review Board (IRB) chair in various research environments. Her comprehensive background demonstrates a commitment to both clinical practice and advancing medical knowledge in pediatrics and related fields.
With over 30 years of experience spanning product management, engineering, business development, and general management, Dilip Daswani has led initiatives across industries including Financial Services, Telecommunications, Energy, and Consumer Products. As CEO of Qliktag Software, Inc., Dilip drives the vision of enabling companies to tokenize and digitally enhance their physical products through a powerful SaaS platform.
Previously, Dilip served as Vice President of Corporate Development at Triple Point Technology, a privately held company focused on providing software solutions for the Energy / Commodity Trading and Risk Management (E/CTRM) sector where he spearheaded business expansion through alliances, resellers, and acquisitions, contributing to the company’s $150 million in sales. Before that, he was President of Energy Crossroads, which was successfully acquired by Triple Point Technology in 2001.
Apurva Kalia brings over 35 years of experience as a technology pioneer, innovator, and strategic leader, with a proven track record of building scalable software platforms, defining technology strategies, and leading dynamic global teams. His expertise spans Artificial Intelligence, Machine Learning, and computational biology, delivering groundbreaking results across industries. Apurva excels in leveraging AI/ML techniques such as generative AI, natural language processing, and feature engineering to drive innovation. He has successfully implemented cutting-edge solutions, including drug-target prediction models and molecular property predictions, achieving state-of-the-art results in his PhD research at Tufts University in Systems and Computational Biology.
As Chief Research Officer at Lumina AI Inc., Apurva created innovative, scalable solutions for at-scale data ingestion and embedding, achieving remarkable efficiency gains while securing substantial seed funding. Previously, at Cadence Design Systems, he led the R&D team for Advanced Verification Solutions, growing it from the ground up to over 200 members globally. Under his leadership, Cadence's flagship product reached $180M in annual revenue, and innovative technologies, such as patented fault simulation solutions, were introduced. His efforts also resulted in a 300% performance improvement in logic simulation over five years, strengthening partnerships with major clients like Apple, Samsung, and Texas Instruments.
Apurva's strength lies not only in his technical acumen, which includes cloud computing, parallel architectures, and complex algorithms, but also in his ability to build and scale high-performance teams. Over two decades, he has fostered team environments with attrition rates below 7%, reflecting his commitment to empathetic and hands-on leadership.
Beyond his corporate impact, Apurva is a passionate advocate for STEM education. He founded India STEM Foundation and Techtronics Education, initiatives that have impacted thousands of students and ignited interest in robotics-based learning across India. Apurva’s contributions are further highlighted by numerous publications, including research on molecular modeling and metabolomics, and patents that showcase his pioneering work in advanced verification and AI-driven solutions.
Thomas Mathew is a seasoned technology leader with over two decades of experience building large-scale, AI-powered platforms and leading high-performing engineering organizations across AdTech, HRTech, and eCommerce.
Prior to joining ThinkBio.Ai, Thomas led the global Ads organization at Indeed, where he scaled platforms supporting a $3B+ business to over $6.5B in revenue over three years. He has held senior engineering leadership roles at Rakuten, Yahoo, and i2 Technologies, delivering large-scale, mission-critical systems—supporting thousands of nodes, millions of transactions per day, and strict SLAs. Over his career, Thomas has built and scaled distributed engineering organizations from the ground up, growing teams from 30 to 400+ across North America, APAC, and EMEA regions. He has successfully integrated complex M&A technology ecosystems, led multi-billion-dollar platform modernizations, and architected next-generation AI/ML systems on scalable, cloud-native infrastructure.
At ThinkBio.Ai, Thomas is focused on building Data and AI platforms. With a Ph.D. from IIT Madras and a track record of delivering large-scale software systems, he brings a rare blend of academic rigor, deep technical expertise, and global leadership experience to tackling healthcare’s complex, data-intensive challenges with AI at scale.
Dr. Bobby J. Cherayil is a graduate of Christian Medical College (CMC), Vellore, India, where he received the MBBS and MD degrees, with specialization in pediatrics. He did post-doctoral training in molecular biology and immunology, initially at the Whitehead Institute for Biomedical Research in Cambridge, Massachusetts, and subsequently at the Massachusetts General Hospital (MGH) Cancer Center in Boston. After completing clinical residency training requirements at the Columbia-Presbyterian Medical Center, New York, he returned to MGH to establish an independent laboratory in the Department of Pediatrics.
His research interest is in host-microbial interactions in the gastrointestinal tract, with a special focus on the innate immune response to Salmonella infection. His research has been supported by the National Institutes of Health (NIH) as well as private foundations and has resulted in the publication of over 70 scientific papers, review articles and book chapters. He is an Associate Professor of Pediatrics at Harvard Medical School (HMS), and a Member of the Harvard-MIT Health Sciences and Technology Faculty.
He has served as Associate Editor and Section Editor for the Journal of Immunology, a member of the Editorial Board of Infection and Immunity and an ad hoc reviewer for several other journals such as Blood, Journal of Clinical Investigation and Nature. He has participated in multiple national and international scientific review committees, including for the NIH, Oxford University, the C. Doppler Forschungsgesellschaft, the Agence Nationale de la Recherche and the Tyrolean Science Fund. In addition to his laboratory research, Dr. Cherayil has been actively involved in teaching and science communication throughout his career. He served as the co-director of two immunology courses at HMS and was a member of the faculty of annual vaccine courses held in India and South Africa. He is the author of The Logic of Immunity, a brief introduction to immunology for the general audience that was published by the Johns Hopkins University Press in 2024.
Pradeep Palazhi is an experienced entrepreneur with 30-plus years in various sectors, including healthcare, genomics, precision medicine, synthetic biology, SaaS, and fintech. He has founded or played key roles in several successful companies, such as Loyale Healthcare, ePAY Healthcare, Saath.Care, HealthVidvan, CASHNet, American HealthNet, and Calsoft. Pradeep specializes in building large platforms and SaaS products, as well as managing extensive solutions organizations. He is particularly passionate about developing practical solutions to address significant healthcare challenges that impact patient care and quality of life. His vast business experience and connections span across the US, UK, and India.
Currently, Pradeep serves as the Co-Founder and CEO of ThinkBio.Ai®, Inc., where he focuses on digital biology and precision medicine platforms and solutions. Under his leadership, ThinkBio.Ai® utilizes AI to drive innovations in the biotech, pharmaceutical, and healthcare sectors..
Dan Peterson’s illustrious 55-year career in technology came to a close in 2020 with the sale of Loyale Healthcare, the fourth and final company he founded and led. His entrepreneurial journey included the creation of CASHNet, PBL Associates, and Spectral Systems, each leaving an indelible mark on the industry. Dan’s approach to business and life is rooted in two core principles – harnessing technology responsibly to enhance the lives of customers and contribute positively to the world and believing that sustainable success comes from “doing well by doing good” – benefiting both the people served and the team members who drive that success.
Now based in Santa Fe, NM, Dan remains an active force in the local music and museum community and is passionate about sailing, scuba-diving and flying. He continues to engage his sharp mind through his work with ThinkBio.AI®, demonstrating his ongoing commitment to innovation and progress.
Sam Santhosh is a visionary entrepreneur with a remarkable 35-year track record of building successful companies across the United States and India. His career spans two distinct phases: the first 20 years in the IT industry, where he founded and took California Software Co Ltd (Calsoft) public in India, and the subsequent 15 years leading the genomic revolution in India. Through his incubator, SciGenom Labs in Kochi and San Francisco, Sam launched multiple companies leveraging Next Generation Sequencing (NGS) and Bioinformatics. His most notable venture, MedGenome, incubated in 2010, raised $120 million from leading venture capital firms and established itself as India’s foremost genomic diagnostics and research company. This success earned Sam the moniker ‘Genome man of India’.
Currently, Sam continues his entrepreneurial journey by incubating startups through SciGenom Labs and promoting genomic research and education via the SciGenom Research Foundation (SGRF), a non-profit trust he established in 2011. His latest passion project involves creating a medicinal plant garden in his hometown of Trichur, Kerala, inspired by the 17th-century work ‘Hortus Malabaricus’ (Garden of Malabar). A mechanical engineer with an MBA from IIM Calcutta, Sam divides his time between San Francisco and Kochi.
Kevin is a seasoned executive leader with extensive experience across Healthcare, Technology, FinTech, and Financial Services industries. His impressive career includes roles as CEO, President, CFO, and Managing Director/Partner, as well as Board of Directors positions. Kevin has a strong track record of building substantial enterprise value through various strategies, including growth capital funding, M&A, organic growth, cash flow enhancements, business model transformation, and turnarounds. His notable achievements include successfully leading Loyale Healthcare as CEO & CFO, where he built thriving SaaS Enterprise Technology and FinTech Payments businesses, securing major healthcare networks as customers and ultimately achieving a successful exit. As CEO & CFO of Paradigm Outcomes, he improved clinical outcomes and customer savings to industry-leading standards, doubling revenue and EBITDA, which led to a $300+ million private equity acquisition.
Throughout his career, Kevin has demonstrated expertise in value acceleration and realization, governance roles, capital readiness and funding, and sell-side M&A. As a Senior Partner at Ernst & Young, he provided consulting and audit services to many of the firm’s largest clients, managing complex projects including large-scale M&A. His industry experience spans Healthcare, Financial Services, Technology, Professional Services, and Life Sciences/Pharma. Kevin’s comprehensive skill set includes strategic advisory consulting, business strategy development, risk management, and executive mentoring. His proven ability to drive growth, optimize operations, and create monetizable value positions him at the forefront of today’s dynamic business landscape.
Michael Evans is a seasoned business leader with over three decades of experience in finance and consulting. He spent 34 years as a Senior Partner at Ernst & Young (EY), where he served as Global Industry Leader for the Real Estate, Hospitality and Construction practice. At EY, Michael held senior management roles in the US and Latin America, helping clients improve financial reporting systems, enhance performance, and streamline operations across various service lines.
Currently, Michael is the Managing Director, Chief Financial Officer, and board member for Newport LLC, a partnership focused on middle market companies’ growth and performance. He also serves on several company boards, including one specializing in Artificial Intelligence. A CPA and attorney, Michael shares his expertise as a lecturer on business planning and succession, and as an author for Forbes.com on private company growth. His diverse background and ongoing engagement with emerging technologies provides him with a unique perspective on business strategy and growth.
As the CTO and founder of Feathersoft Info Solutions Private Limited, Sudhish Chandran is the driving force behind the company’s technology vision and strategy. He spearheads future technology development, focusing on the incubation of emerging technologies, fostering an innovation ecosystem, and creating industry alliances. With over a decade’s experience in delivering software solutions and cloud architecture to niche industries such as Agritech, Fintech, and Biotech, Sudhish is a seasoned executive. His expertise spans Big Data, Hadoop, AI / ML, Application Management, Enterprise Monitoring, IT Infrastructure, and Cloud Computing. Sudhish excels in implementing risk-free, server-less cloud migrations using agile methodologies.
Sudhish is experienced in building high-performance, large-scale real-time systems, microservices, and web applications. He has a stellar track record of assembling highly skilled development teams and delivering innovative solutions tailored to business needs. He is adept at crafting product and technology strategies, leveraging a strong background in consumer internet/mobile and Cloud/SaaS/Enterprise technologies, and establishing world-class technology teams from the ground up. Sudhish leads all aspects of the product lifecycle, from development and quality assurance to presales and customer support, and excels in managing geographically distributed teams.
Ajikumar “Aji” Parayil is an entrepreneur with more than 20 years of experience in technological innovation and commercialization. He is the Founder and Chief Executive Officer of Manus, the proven BioAlternatives scale-up platform. He invented Manus’ core technology platform at the Massachusetts Institute of Technology (MIT), launched Manus in 2011, and led the successful commercialization of multiple products – BioAlternatives – made through precision fermentation. Notably, Aji has pioneered several novel methods for engineering chemistry using biology to biomanufacture complex natural chemicals. His contributions are reflected in more than 200 U.S. and international granted and pending patents, as well as more than 60 publications in biotechnology and chemical biology. He is an elected fellow of the American Institute of Medical and Bioengineering (AIMBE) and received the Society of Industrial Microbiology’s (SIMB) Raphael Katzen Award in 2021 for enabling the deployment and commercialization of biotechnology to produce fuels and chemicals from renewable resources.
After obtaining undergraduate (1990) and graduate degrees (1996) from Simon Fraser University, Dr. Sidhu worked at Genentech, first as a postdoctoral fellow (1996-1998) and subsequently as a principal investigator. At Genentech, he led the development of synthetic antibody libraries that have proven to be a valuable source of potential therapeutics. Dr. Sidhu is an expert in phage display technology and structure-based combinatorial protein engineering. His research has been instrumental in establishing greatly improved technologies for therapeutic antibody development and engineering of alternative scaffolds.
From 2008 to the present, Dr. Sidhu has led research groups at the interface of industry and academia, through affiliations with the Universities of Toronto and Waterloo. These efforts have led to the engineering of thousands of drug-grade antibodies targeting hundreds of proteins associated with numerous diseases. Many of these have been successfully translated into therapeutic candidates through collaborations with industry partners. Others have enabled the foundation of startup companies, including Dextera, Northern Biologics, Pionyr, Antlera, Aarvik, EPOK, and Axoiya. Most recently, Dr. Sidhu has further strengthened the scope of his industrial efforts through the formation of Simisco Biosciences, a unique platform company that houses a large portfolio of synthetic antibodies and cutting-edge technologies to develop these as therapeutics. Simisco is working with partners across the globe to apply advanced antibody engineering technology to diverse areas of unmet medical needs.
Dr. Sidhu holds nearly 50 patents and has over 300 peer-reviewed publications. He won the University of Toronto’s Inventor of the Year Award in 2012 and the Protein Society’s Christian B. Anfinsen Award in 2015. He became a Fellow of the National Academy of Inventors in 2020.
Dr. Jame Abraham, MD, FACP, is a distinguished medical professional who currently is Chair of Hematology/Medical Oncology at Cleveland Clinic. In this pivotal role, Dr. Abraham is dedicated to recruiting and developing staff while guiding the department's focus on patient access and multidisciplinary care. Alongside these responsibilities, he continues to serve as a Professor of Medicine at Cleveland Clinic Lerner College of Medicine. Prior to assuming his current position, Dr. Abraham made significant contributions as the Director of the Breast Oncology Program at Cleveland Clinic's Taussig Cancer Institute and Co-Director of the Cleveland Clinic Comprehensive Breast Cancer Program. His leadership in these roles paved the way for his current appointment.
Dr. Abraham's journey in medicine began at Calicut Medical College in Kerala, India, where he earned his medical degree. He then furthered his education and training in the United States, completing a residency at the University of Connecticut. His specialized expertise was honed through fellowships in hematology at the National Heart, Lung, and Blood Institute and in medical oncology at the National Cancer Institute.
Before joining Cleveland Clinic in 2013, Dr. Abraham held several prestigious positions at West Virginia University. There, he served as the Chief of Hematology/Oncology, Professor of Medicine, and was honored as the Bonnie Wells Wilson Distinguished Professor of Breast Cancer Research. As a researcher, Dr. Abraham has made substantial contributions to the understanding and treatment of breast cancer. He has served as the national principal investigator for multiple breast cancer clinical trials, pushing the boundaries of medical knowledge in this critical area. His expertise is further evidenced by his prolific academic output, having published and presented over 200 papers throughout his career. Additionally, Dr. Abraham's influence extends to medical literature as the Founding Editor of The Bethesda Handbook of Clinical Oncology, a valuable resource for oncology professionals.
Dr. Abraham's expertise and leadership are recognized nationally through his involvement in several key committees. He serves as a member of the National Comprehensive Cancer Network (NCCN) Breast Cancer Committee, contributing to the development of guidelines that shape breast cancer care across the country. His role as Vice Chair of NRG Oncology's Research Strategy Committee allows him to influence the direction of oncology research on a broad scale. Furthermore, his membership in NRG Oncology's Breast Cancer Working Committee and his position as Vice Chair of the National Surgical Adjuvant Breast and Bowel Project (NSABP) Research Review Committee demonstrate his deep involvement in shaping the future of breast cancer research and treatment.
Throughout his career, Dr. Jame Abraham has demonstrated an unwavering commitment to advancing breast cancer research and treatment. His combination of clinical expertise, research acumen, and leadership skills makes him an invaluable asset to the field of oncology and a respected figure in the broader oncology community.
Vinod A. Pullarkat, MD, MRCP is Professor of Hematology and Hematopoietic Cell Transplantation at City of Hope. After graduating from Calicut Medical College India, he did his training in Hematology at the University of Southern California. Dr Pullarkat is an internationally recognized expert in the field of acute leukemia and bone marrow transplantation. Dr. Pullarkat’s clinical research interests include treatment of acute leukemia, stem cell transplantation, bone marrow failure and autoimmune hematologic disorders. His basic research focusses on new drug development for acute leukemia. Dr. Pullarkat has authored over 200 scientific articles in various peer reviewed journals and he serves as principal investigator for multiple clinical trials at City of Hope.
Mr. Subramonian underwent his basic medical training and general surgical training in India. Subsequently he underwent higher training in Urology in the UK. He holds Fellowship of the Royal College of Surgeons (FRCS) in Urology and pursued Higher Surgical Training in London, with a particular focus on endoscopic surgery for stone disease and laparoscopic procedures. His formative years included tenures at King's College, London, and St. George's Hospital. Notably, he earned a coveted traveling scholarship from the British Urological Foundation, honing his skills at the vanguards of innovation in the USA, namely Cleveland Clinic and John Hopkins Hospital.
Mr. Subramonian has served as a Consultant Urological Surgeon at University Hospital Birmingham for the last 20 years. He's made significant contributions to the department as the Clinical Director of Urology and Stone Lead. His expertise extends to spearheading the management of intricate kidney stone cases, establishing the Queen Elizabeth Hospital as the preeminent referral centre for the West Midlands region. Recognized for pioneering endourological procedures and introducing revolutionary healthcare management practices, he adeptly harnesses the power of new technology and IT.
With a track record comprising over 1200 PCNL procedures for stones and 3000 Flexible Ureteroscopies, Mr. Subramonian is committed to the mentorship of consultant colleagues. His research contributions include over 42 scholarly articles, including 2 paradigm-shifting pieces, with a substantial citation count. Additionally, he has penned 3 authoritative textbook chapters. Notably, Mr. Subramonian founded the esteemed Stone fellowship program, cultivating a cadre of urologists now leading the charge in stone specialization in the UK and beyond.
As an elected member of the national executive committee of the British Association of Urological Surgeons (Stones & Endourology subsection), Mr. Subramonian currently holds the esteemed position of Chair of the British Association of Urology, Endourology subsection. As an experienced Academic Urologist, he is frequently invited as faculty and Guest Lecturer at national and international meetings.
Dr. Akash is a highly accomplished physician with a strong academic foundation, having completed his MBBS from the All India Institute of Medical Sciences (AIIMS) and his MD in General Medicine from the prestigious Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER). These premier institutions reflect his competitive background and drive for excellence. With four years of clinical experience, Dr. Akash has developed expertise in critical care, disease prevention, and multidisciplinary collaboration, working efficiently in high-pressure environments such as ICUs and emergency services. His experience during the COVID-19 pandemic and in various critical care settings has solidified his ability to lead medical teams, manage complex cases, and deliver patient-centered care.
Beyond his clinical skills, Dr. Akash is deeply passionate about the evolving role of healthcare technology and artificial intelligence in the medical field. He is eager to be at the forefront of this revolution, leveraging these advancements to enhance patient care on a wider scale. His vision is to contribute to innovations that make healthcare more efficient and accessible, ultimately improving outcomes for a broad patient population. With his strong leadership, communication skills, and commitment to staying at the cutting edge of medical practice, Dr. Akash is well positioned to make a significant impact in the health tech sector.
Dr. Raju holds a medical degree from Government Medical College, Calicut, followed by a Post-Graduate degree in Management from the Tata Institute of Social Sciences (TISS), Mumbai. He began his corporate career in the medical and pharmaceutical sectors, working as a Pharmaceutical Physician for globally recognized Fortune 500 companies like Pfizer, AstraZeneca, Wockhardt, and Menarini. Throughout his tenure, Dr. Raju contributed to various areas, including Medico Marketing, Strategy, and Innovation. He was part of the teams that successfully launched over 50 pharmaceutical products across the Asia Pacific market, including the launch of Forxiga, India's first SGLT2 inhibitor, which became a blockbuster drug within a year of its launch.
With a shift towards Digital Health, Dr. Raju became the Medical Lead for South Asia at Wolters Kluwer, a leading company in clinical decision support systems used by over 2 million doctors across 180 countries. In this role, he collaborated with hospitals and health systems across South Asia to manage the implementation of the advanced system, earning recognition from the CEO for his outstanding collaboration in the Asia-Pacific region.
Dr. Raju later took on the role of Director of Growth at Twin Health, a diabetes digital therapeutics company, where he drove growth strategies. His next move brought him to Dr. Reddy's Laboratories, an Indian multinational pharmaceutical company, where he led the Global Innovation Portfolio focused on Medical Devices and Digital Therapeutics, spearheading the development and launch of groundbreaking innovations to meet the evolving needs of the healthcare sector. Currently, Dr. Raju is consulting and leading the KGDC Project (Kerala Genome Data Centre) under the Kerala Development and Innovation Strategic Council (KDISC). This ₹500 crore government initiative aims to position Kerala as a leader in genomics and bioeconomy.
In addition to his corporate roles, Dr. Raju has authored numerous scientific publications and serves as a mentor and advisor to various startups and health tech investors. He has also been a speaker, moderator, and panelist at numerous scientific and technology conferences. As a Mentor for Femtech Labs in London and an Advisor for the EU-India Innocenter, he actively supports healthcare startups. At ThinkBio.Ai®, Dr. Raju leads enterprise sales for software solutions targeting Life Sciences, Pharma, and Hospitals.
Prior to ThinkBio, Aashind co-founded Saath Care, a consulting firm focused on genomics-driven digital health solutions for chronic illnesses such as oncology and autoimmune disorders. At SciGenom Labs, he further honed his expertise in healthcare innovation, developing the Kerala Genome Data Center and crafting investment strategies in genomics, biologics, and synthetic biology. His role also involved advising healthcare companies on expansion strategies. Earlier, Aashind gained invaluable experience at Areté Advisors—acquired by Bain & Company—where he guided prominent private equity and healthcare clients through market expansion, growth strategy, and due diligence.
Aashind holds a Bachelor’s degree in Chemistry from St. Xavier’s College, Mumbai. Outside of his professional pursuits, he is an avid reader with a keen interest in the intersections of technology, biology, and wellness. Recognised for his contributions to science and education, Aashind remains committed to advancing knowledge and fostering innovation in healthcare.
Vidhi Malik is the Principal Computational Biologist at ThinkBio.Ai®, where she leads a team of innovative computational biologists in advancing AI-driven bioinformatics research. With a focus on harnessing cutting-edge technologies to analyze complex bioinformatics data, Vidhi’s work transforms data into actionable insights that fuel innovation in genomics and precision healthcare.
Vidhi holds a PhD from IIT Delhi, where her research on molecular targets for cancer therapeutics led to critical advancements in precision oncology, including the development of machine learning models for predicting patient outcomes. As a Postdoctoral Fellow at Brigham and Women’s Hospital and Harvard Medical School, she has conducted pioneering research on Chronic Obstructive Pulmonary Disease (COPD), focusing on the functional genomic responses of lung cells to genetic mutations.
At ThinkBio.Ai®, Vidhi leverages her expertise in SNP-to-Gene mapping, multi-omics integration, single-cell sequencing, molecular modeling, and machine learning, positioning ThinkBio.Ai® at the forefront of bioinformatics and personalized medicine. Her leadership fosters a collaborative environment that pushes the boundaries of computational biology, enabling the transformation of complex bioinformatics data into actionable insights and helping ThinkBio.Ai® deliver meaningful advancements in bioinformatics and patient care.
Dr. Vrinda Venu is a senior computational biologist at ThinkBio.Ai®, where she leads efforts to develop AI-powered pipelines that extract biological insights from genomic, transcriptomic, and epigenomic datasets bridging the gap between fundamental research and real-world applications.
Dr. Vrinda began her research journey during her integrated BS-MS program in Biology at IISER Thiruvananthapuram. She was a recipient of the prestigious KVPY fellowship awarded by the Department of Science and Technology, Govt. of India (2009 - 2014) and this recognition enabled her to pursue research internships at leading research institutions in India including JNCASR Bangalore, and RGCB Thiruvanathapuram. She conducted her PhD research at the Friedrich Miescher Laboratory of the Max Planck Society in Germany through the international PhD program in Tuebingen. Her doctoral research explored the role of meiotic recombination on adaptive divergence and speciation offering key evolutionary genomics insights into this complex mechanism. As a postdoctoral researcher at Los Alamos National Lab in the United States, Dr. Vrinda worked at the forefront of 4D genomics, investigating dynamic three-dimensional genomic changes in response to viral infections and therapeutic interventions.
At ThinkBio.Ai®, Dr. Vrinda's expertise in evolutionary genomics, epigenomics, and 4D genomics drives the development of innovative solutions that advance clinical research and precision medicine.
Shahina is a computational biologist with a strong educational background, holding a Ph.D. in Computational Biology and Bioinformatics from the University of Kerala, along with a Master's and Bachelor's degree in related fields. As part of her PhD program she developed different deep learning models to classify genome sequences of different organisms from their chaos game representation (CGR) images and also studied the effect of different generative adversarial networks and data augmentation techniques on CGR images of biosequences.
With over 7 years of work experience, her expertise lies in Next Generation Sequencing data analysis, machine learning, and deep learning. Professionally, she has held various roles, including Bioinformatician, Bioinformatics Intern at Khalifa University, IT Instructor, and Support Engineer.
She holds certifications in Genomic Variant Analysis & Clinical Interpretation, NIH Clinical Research Training, ITIL Foundation, Oracle Certified Associate and Microsoft Certified Professional. Her unique blend of research and industry experience makes her a valuable asset to organizations in bioinformatics, computational biology, and data analytics.
Currently, Dr. Shahina serves as a Computational Biologist at ThinkBio.Ai®, where she works on projects that harness computational techniques to address pressing biological questions.
Dr. Sana Munquad is a computational biologist at ThinkBio.Ai®, where she leverages advanced machine learning and artificial intelligence (AI) techniques to analyze genomic data, advancing the field of personalized medicine. Her work focuses on developing AI-driven models to identify critical biomarkers for predicting drug response, thereby tailoring therapeutic strategies to individual patient profiles.
Dr. Munquad’s academic journey began with a BTech in Biotechnology from Integral University, Lucknow, in 2012, followed by an MTech in Bioinformatics from Maulana Azad National Institute of Technology, Bhopal, in 2015. Awarded the prestigious GATE PhD grant, she completed her PhD in Bioinformatics in 2024 at the National Institute of Technology, Warangal. Her research expertise spans genomic data mining, machine learning model development, and drug target and response prediction.
As high-throughput omics technologies produce vast data, Dr. Munquad’s team at ThinkBio.Ai® focuses on developing computational methods to extract valuable insights, helping to decode complex molecular mechanisms and disease biology. In cancer personalized medicine, her work aims to identify specific biomarkers that predict therapeutic responses, addressing a central challenge in personalized oncology. Through these efforts, Dr. Munquad is at the forefront of using AI to unlock the potential of precision medicine, ultimately aiming to improve patient outcomes with targeted treatment approaches.
As a Scientist in R&D Healthcare and Bioinformatics at ThinkBio.Ai®, Chinju John brings expertise in computational biology and artificial intelligence to advance healthcare solutions. She has a Master's in Computational Biology and a B.Tech in Computer Science and Engineering. With over 9 years of combined experience in academia and industry, Chinju actively contributes to scientific advancement through her work as both an author and reviewer for international journals and conference publications. Her research Interests include Bioinformatics, Deep Learning & Explainable AI.
Chinju’s unique combination of computer science expertise and biological knowledge positions her at the forefront of healthcare innovation at ThinkBio.Ai®, where she applies advanced computational methods to solve complex biological challenges.
Anupa Sunny is an R&D Scientist at ThinkBio.Ai®, advancing innovation in single-cell transcriptomics through the development and benchmarking of both foundation models and task-specific models for complex biomedical challenges. With a career spanning computational complexity, formal verification, machine learning, and applied labor economics, Anupa thrives on tackling diverse, interdisciplinary problems and turning ambitious ideas into actionable solutions.
She earned a PhD in Computer Science from the Université Paris Cité, specializing in computational complexity theory, focusing on the interplay between randomness and quantum entanglement. She did her M.Sc. in Computer Science from the Chennai Mathematical Institute and B.Tech in Electrical and Electronics Engineering from the Govt. Model Engineering College, Thrikkakara.
Before joining ThinkBio.Ai®, Anupa conducted postdoctoral research at the Indian Statistical Institute, Kolkata, applying machine learning to formal verification, and worked at the Asian Development Research Institute, Patna, applying AI to labor economics. By blending deep theoretical expertise with a readiness to embrace new challenges, Anupa helps position ThinkBio.Ai® at the forefront of precision medicine innovation.
Manoj Krishnan (Kris Manoj) has built a career focused on business innovation and strategic development across multiple sectors. His professional work has primarily centered on creating and scaling business solutions in technology, sustainability, and entrepreneurial ecosystems.
Most recently, at BillionLives Business Initiatives, a social impact startup, he led New Business Initiatives, driving its transformation into an ESG Tech company. He was a founder of Greenturn Idea Factory, a hardware tech startup, where he managed the business and operational aspects. The company was selected for accelerator programs by Facebook India and Dubai Smart City, and received recognition from various organizations including JLL.
His consulting work has spanned multiple domains. At Nuivio Ventures, he worked on identifying innovative business solutions, and at Microsoft Accelerator, he managed a program supporting large startups with an average ARR of $1 million. Recently, he was working with NIC Mauritius, developing a microfinance market entry strategy for the firm that involves designing innovative products, mapping process workflows, and coordinating technology implementation.
Throughout his career, Manoj has demonstrated capabilities in startup ecosystem development, corporate innovation, strategic consulting, and technology-driven business solutions. His work has consistently focused on bridging technological innovation with practical business strategies. Manoj holds an MBA degree from University of Oxford and an engineering degree from College of Engineering, Trivandrum.
Dr.Arun combines nearly two decades of experience in Medical communication, public relations and marketing where he was involved in shaping brand reputation, narrative design, engagement cultivation on digital and traditional channels.
Having trained as a pharmaceutical scientist and later as a communications strategist, Dr.Arun has worked on global brand campaigns alongside clinical research operations and healthcare IT programs consistently delivering measurable return on investment for the clients.
He obtained his PhD from Annamalai University in Pharmaceutical Sciences an MBA with specialization in Marketing and Systems Management and a Master’s degree in Pharmacy Practice from Rajiv Gandhi University where he graduated top of the university.
At ThinkBio.Ai, Dr.Arun integrates science, storytelling, and strategy to advance the company’s mission and voice in the biopharma and healthtech ecosystem.
As a Biomedical Scientist at ThinkBio.Ai®, Mohan brings expertise in experimental cancer research and experience in bioinformatics to help with developing AI tools to advance healthcare. He holds a PhD from Rajiv Gandhi Centre for Biotechnology and has done postdoctoral research at Cedars-Sinai Medical Center and The University of Oklahoma Health Science Center.
At the company, Mohan ensures biological relevance and scientific rigor in AI tool-development pipeline, identifies impactful biomedical use cases, evaluates the reliability and appropriateness of the AI tools for preclinical and clinical research applications. He helps in the development of scientific framework that helps AI-engineering teams in building tools to meet real world translational research needs. In addition, he contributes to business growth by identifying potential clients and strategic opportunities where the company’s tools can deliver more value.
Mohan has authored multiple peer-reviewed publications and actively contributes to the scientific community as a reviewer for international journals. With a blend of experimental and computational insights, he is committed to accelerating biomedical innovation through interdisciplinary collaboration.
Baiju Sankaran is a seasoned professional with deep expertise in Product Engineering and Digital Transformation service delivery. With a career marked by strategic foresight and operational leadership, he has consistently driven success across a broad spectrum of global engagements. In his previous leadership role, Baiju was instrumental in formulating and executing high-impact initiatives for both Product and Enterprise clients, managing cross-functional and geographically distributed delivery teams to ensure excellence in execution and client satisfaction.
A key contributor to organizational growth, Baiju played a pivotal role in establishing and scaling verticals such as Healthcare and Education. His efforts in building robust technical and functional capabilities within these domains have positioned his teams as trusted partners to clients. Additionally, his close collaboration with sales and marketing functions significantly accelerated business development, enhancing the organization’s market presence. Baiju is also known for his ability to nurture long-term client relationships, consistently delivering value through innovation and a strong commitment to client success.
As an experienced Healthcare IT professional with more than 25 years in the domain, including a decade in the US Healthcare ITES sector and 15 years focusing on US healthcare products and services, Unnikrishnan’s expertise covers a wide range of areas, including Electronic Medical Records (EMRs), Laboratory Information Systems (LIS), Revenue Cycle Management (RCM), Radiology, and Homecare management applications.
He is an experienced professional with expertise in project and program management, account management, product support, and software implementation. Over the years, he has successfully led large-scale healthcare technology deployments, working closely with cross-functional teams to optimize workflows, improve service delivery, and ensure smooth technology adoption. His leadership has been pivotal in driving customer success, managing complex situations, and keeping teams focused on delivering results. With a bachelor's degree in economics and certifications in ITIL, Six Sigma Green Belt, and Certified Professional Coder (AAPC), along with training in Agile and PRINCE2 methodologies, Unnikrishnan combines strategic insight with practical execution. He is dedicated to developing scalable solutions that address healthcare challenges, improve operations, ensure compliance, and enhance patient care.
Pratheek holds a Master's in Biomedical Engineering (Neuroscience focus) from Duke University NC, USA and an MBA from IIM Ahmedabad, India.
He started his career at Neuroplus as the Product Owner for a EEG-based adaptive learning system for children with learning disabilities such as ADHD, where in addition to charting the product roadmap and strategy, he contributed to the firmware for a prototype device while authoring the code for the user application, data operations, and billing integrations.
Post his MBA, he worked as a marketplace PM at Microsoft, owning the Australian and Canadian markets (then ARR >$200M) and holding responsibility for financial and non-financial KPIs. He worked closely with teams in emerging AI and ML technologies such as BERT and RoBERTa, across the entire ad-auction stack such as selection, relevance, augmentation, etc.
He then joined Saath as the Head of Product, where he helped build and deliver an online companion platform for patients suffering from chronic diseases such as breast cancer and autoimmune diseases. He owned the product roadmap and strategy, as well as tactical implementation steps such as conducting user interviews, developing the UI/UX flows, and writing the feature specifications.
Most recently, he served a Product and Growth role with Simplismart, an Accel-backed AI infrastructure startup that has developed the fastest inferencing engine globally on NVIDIA chips. His role there was to engineer AI and MLOps solutions for large corporate clients while nurturing the sales pipeline and aiding in developing the long-term product roadmap.
Dr. Kamalika is an accomplished research scientist managing the Data Translation Team at ThinkBio.Ai. During her PhD (Biotechnology) from Saha Institute of Nuclear Physics (DAE), she investigated molecular basis of the rare neurodegenerative disorder, Huntington’s disease using advanced cell biology and proteomics techniques. Her groundbreaking research established enhancing autophagy clearance pathways towards facilitating removal of the toxic mutant Huntingtin protein aggregates, offering a novel therapeutic strategy to mitigate disease.
She pursued postdoctoral research at the Centre for Neuroscience, Indian Institute of Science (IISc), Bangalore, focusing on the molecular pathology of Alzheimer’s disease.
Kamalika then took on the role of Principal Investigator at CSIR-IICB, where she led a DST‑SERB–funded cardiovascular research initiative, collaborating with local hospitals and institutions across India. This effort produced high-impact translational findings with promising therapeutic implications.
In 2022, Dr. Roy Choudhury transitioned into industry, joining MagGenome Technologies Pvt. Ltd. as a scientist. There, she drove the development of iron‑nanoparticle‑based kits for biomedical applications.
Leveraging her deep expertise in experimental biology, she currently serves at ThinkBio.Ai, translating complex bioinformatics and machine learning outputs into biologically meaningful interpretations. Her expertise and efforts empower the company to deliver precision medicine advancements and personalized patient care.
Monisha Ashwin is a highly accomplished healthcare professional with over 14 years of experience spanning In Vitro Diagnostics (IVD), oncology, real-world data (RWD), and healthcare product development. With a strong academic foundation in Human Genetics and Oncology, her career has evolved through impactful roles in clinical diagnostics, bio-curation, and end-to-end product management. She has contributed to leading institutions such as the Centre for Human Genetics, Indian Institute of Science, Lilac Insights Pvt Ltd, and Velsera.
Throughout her career, Monisha has successfully led full product lifecycles in oncology data curation, fostering collaborations with clinicians, researchers, and data scientists. She has been instrumental in implementing robust root cause analysis (RCA) frameworks and upholding the highest standards of data quality and scientific accuracy.
In her current role as Product Manager at ThinkBio.AI®, Monisha brings a strategic, innovation-driven approach grounded in deep clinical and technical insight. Her user-centric mindset and cross-functional expertise enable her to drive the design, develop and commercialise impactful AI-powered healthcare solutions.
Monisha is deeply passionate about continuous learning and remains actively engaged with RWE platforms, AI technologies, and cutting-edge product innovation in healthcare.
Dr. Dhanyasree is a medical expert and Consultant Radiologist with extensive clinical experience and knowledge. She holds a strong academic background, having completed her MBBS at the prestigious All India Institute of Medical Sciences (AIIMS) and post-graduation in Radiology at Kovai Medical Centre and Hospital, Coimbatore.
Her stint at esteemed institutions such as Aster MIMS, Kannur instilled in her, a passion for leveraging technology to enhance healthcare outcomes. She seeks to combine her radiological expertise with technological innovations to drive transformative change in the healthcare landscape.
During her residency, she was actively exposed to AI-related conferences and advancements, fostering her interest in the intersection of medicine and artificial intelligence. This unique blend of medical expertise and AI awareness enables her to provide invaluable guidance and mentorship to the team, driving the development of innovative AI-powered healthcare solutions
Dr. Anagha is an Obstetrics and gynaecology resident with a strong foundation in basic medical sciences and a steadfast commitment to advancing women’s health. Her residency training spans the management of routine pregnancies, complex obstetric conditions, and exposure to acute emergencies in casualty and critical care settings. She has cultivated particular interests in maternal– Fetal medicine, reproductive endocrinology, and the integration of cutting-edge technology into clinical workflows to improve patient outcomes. Beyond her clinical role, Dr. Anagha is deeply engaged in research, medical education, and innovative approaches to healthcare delivery. With a blend of scientific rigor, analytical thinking, and adaptability, she aims to contribute to the future of obstetric practice by bridging the gap between evidence-based medicine and emerging technological solutions.
Dr. Gopinath is a physician and healthcare innovator dedicated to transforming patient care through evidence-based and patient-centric solutions. With expertise in lifestyle diseases, infectious diseases, complex diagnostics, and oncology, he integrates telemedicine, recent advances and scalable innovations to make high-quality healthcare more accessible. Driven by a vision to redefine healthcare delivery, Dr. Gopinath is committed to building impactful, inclusive, and future-ready medical solutions.
Dr Parvathy is a graduate of PDU Government Medical College Rajkot where she earned her MBBS following which she received MD in Pathology from BJ Medical College, Ahmedabad. With four years of experience in the field of pathology she brings a deep foundation in clinical expertise to the forefront of AI driven healthcare solutions.
At ThinkBio.Ai, Dr Parvathy helps in the integration of computational methods with pathology for development of innovative tools that enhance diagnostic accuracy, efficiency and scalability. She is passionate about bridging the gap between medical science and artificial intelligence to drive forward diagnosis, research and development that has real world impact in patient outcomes.
Samish Karunalayam is a Chartered Accountant with over 18 years of experience, primarily in the IT industry. He specializes in M&A, Financial Planning & Analysis, Auditing, Accounting & Controllership, Treasury Management, and Stakeholder Management.
Most recently, Samish served as the Head of Finance at Aspire Systems Digital (formerly RapidValue), part of the $200M global IT company Aspire Systems. In this role, he played a pivotal role in several key functions across the group, bringing deep expertise in strategic financial planning, business insight, and ensuring rigorous financial governance and operational controls. He was instrumental in facilitating the acquisition of RapidValue's digital transformation business by Aspire Systems. Before joining Aspire Systems, Samish held a managerial role at Sagitec Solutions, USA, where he oversaw the successful migration from legacy systems to Oracle NetSuite. He also gained valuable experience at Ernst & Young in Audit, Assurance, and Advisory services, further honing his expertise in financial reporting and compliance.
Dr. Unnikrishnan specializes in the development of therapeutic monoclonal antibodies and cell-based therapies at the intersection of immunotherapy and oncology. He currently serves as Principal Scientist and Head of Operations at the CVJ Centre for Synthetic Biology and Biomanufacturing at the Cochin University of Science & Technology.
Previously, he was part of the founding team at Alstonia Bio, a next-generation immunotherapeutics startup, now rebranded as SIMISCO Biologics-India. At Alstonia, he led the Cell & Genome Engineering Division and contributed the development of preclinical evaluation platforms for next generation engineered mAbs targeting multiple cancer indications.
Earlier, as Senior Research Scientist at Duke-NUS Medical School, Singapore, he led functional genomics–driven target discovery programs focused on T-cell immunotherapy, host-pathogen interactions, and fibrosis biology resulted in the identification of novel druggable targets and invention disclosures. At Duke-NUS Medical School, he has also contributed to the development of novel wound care devices and processes, which led to the co-founding of XFolio PTE LTD, a biomedical venture currently incubated at the National University of Singapore.
Currently he also serves as Consultant to ThinkBio.Ai® Inc, contributing to the development of AI-driven decision support systems for pharmaceutical R&D, and continues to hold an appointment as Adjunct Senior Researcher at Duke-NUS Medical School, Singapore.
Anil Pillai brings over 25 years of experience working with software startups to his role as Senior Vice President of Operations at ThinkBio.Ai®. In this position, he focuses on building high-performing teams in the US and UK to establish ThinkBio.Ai®'s presence in these key regions.
Anil's responsibilities include implementing robust business strategies and operational processes, ensuring regulatory compliance, forging strategic partnerships, and driving business development initiatives. His extensive experience working closely with startup leadership teams will be invaluable as he helps ThinkBio.Ai® execute its long-term growth plans.
Prior to joining ThinkBio.Ai®, Anil held various leadership roles at software startups, including key account manager, VP of Sales, and Head of Operations. He was part of three startups that were later acquired, and he has helped many young companies successfully establish and scale their presence in the US market. Anil is currently also an active advisor to Travancore Analytics Inc., where he mentors the leadership team, manages key client relationships, drives process improvements, and spearheads the expansion of the company's US footprint. Previously, he was the head of operations and part of the leadership team at Rapid Value Solutions Inc., which was acquired by Aspire Systems in 2021.
With his deep understanding of software startup operations and his proven track record of guiding companies through periods of rapid growth, Anil is well-positioned to play a pivotal role in accelerating ThinkBio.Ai®'s expansion into new markets.
Aparna Kochattil is a versatile professional whose career spans product management, business analysis, and marketing across multiple industries. At Thermo Fisher Scientific, she spent over four years as a Product Owner managing multiple scrum teams and overseeing AWS-based cloud and mobile applications. Her experience includes roles at Kaiser Permanente as a Senior Business Analyst, and at Wink Technology Solutions where she led the development of digital magazine platforms and apps.
Earlier in her career, Aparna demonstrated her versatility at Edutech India, where she headed Language Learning Solutions, developing product & go-to-market strategies and managing teams across multiple countries. At the British Council, Chennai, she further honed her strategic communication skills by developing and implementing effective promotional and media campaigns. Her educational background includes an MBA from the University of Madras, a Bachelor of Science degree, and various professional certifications including SAFe POPM and CSPO, reflecting her commitment to continuous learning.
Throughout her career, Aparna has mastered a wide array of skills and tools, from complex project management and cross-functional collaboration to data analysis and stakeholder communication. Her experience combined with her multifaceted background spanning technology, healthcare, media, and education, positions her as a professional who can adapt to diverse business environments and bring valuable cross-industry insights to her work.
Anand Aravind brings over two decades of extensive experience in information technology, with a particular focus on the life sciences, medical devices, pharmaceutical, and healthcare industries. As a trusted client partner and active listener, he excels in leveraging cross-functional team strengths to deliver superior client experiences while driving sustained and profitable growth. His expertise spans presales, sales, program and account management, product development, and operations, making him a versatile leader in the healthcare technology sector.
In his previous role as VP of Operations at Objective Medical Systems, Anand spearheaded the development, sales, and implementation of cutting-edge healthcare solutions. He led initiatives in Electronic Health Records, Population Health Analytics, Remote Patient Monitoring, and AI-driven systems for cardiovascular practices and hospital systems. His leadership ensured compliance with rigorous certification, audit, and clinical quality standards, setting new benchmarks in the industry.
As Director of Sales at NTT Data, Anand demonstrated his exceptional sales leadership by guiding teams in the US Midwest and West regions to achieve over 20% year-over-year revenue growth. His strategic focus on key accounts in the life sciences and medical device sectors, including industry giants like Hospira/Pfizer, Abbott Laboratories, and Stryker Orthopedics, significantly expanded the company's market presence. Anand's unique educational background, combining chemical engineering, an MBA, and advanced training in AI/ML from UT Austin's McCombs School of Business, provides him with a multifaceted perspective that bridges technical innovation with business acumen in the healthcare technology landscape.
Kelan Bomar is a biomedical engineer by training with a strong foundation in research and clinical science. After several years working across various bio-engineering roles, he transitioned into the commercial side of life sciences, where he quickly established himself as an award-winning sales leader. Kelan has driven growth for some of the industry’s most respected organizations, including Stryker and Corning Life Sciences. As Director of Sales at ThinkBio.Ai, he brings a strategic, mission-driven approach to go-to-market execution. A passionate advocate for AI for good, Kelan is committed to advancing transformative technologies that accelerate scientific discovery and improve human health.
Dr Bala Raju's medical career spans over 30 years and has focused on supporting people with physical and mental disabilities. From early on, he integrated the latest healthcare technologies and founded a factory to manufacture medical equipment in India in 2006. The emphasis has been on R&D and PLM, while the product range has continued to grow in line with the government's Make in India movement.
Bala worked in England's National Health Service for 12 years and left as a Hospital Consultant in 2010, to develop private healthcare services in the UK, based on the changing market. His professional network and experience is extensive and will be a catalyst in growing ThinkBio.Ai's presence in the UK and European regions.